EDITOR: | June 12th, 2015 | 3 Comments

Non-invasive diabetes test provides “Miraculins” results through technology

| June 12, 2015 | 3 Comments
image_pdfimage_print

June 12, 2015 — Tracy Weslosky, Editor-in-Chief and Publisher of InvestorIntel speaks to Christopher Moreau, President, CEO & Director for Miraculins Inc. (TSXV: MOM) about the Scout technology, a non-invasive diabetes test and their recent promising results as supported by the joint MIraculins and Amway Scout DS® study being accepted for the 23rd World Congress of Dermatology. In addition to this, a follow-up on the recent good news from the FDA and an update on the $90mm value deal with a Chinese pharmaceutical company, they discuss Miraculins shareholder value and health issues relating to diabetes.

Tracy Weslosky: Today I have the pleasure of speaking with Chris Moreau from Miraculin. Of course, you have the non-invasive diabetes testing — you got ‘the Scout’?

Christopher Moreau: Yes, we have the Scout.

Tracy Weslosky: What I would like to know, but what’s happening with the U.S. FDA?

Christopher Moreau: We had very good news that we had announced, based on our feedback from the U.S. FDA that we are going to continue down a pathway called the de novo path for a class 2 device in the U.S. and we hope to have some additional news soon for the market.

Tracy Weslosky: For those of us that may not understand the biotech industry as well as Chris does, can you tell us what this means for the timeline and why this is such exciting news?

Christopher Moreau: What it means is that typically in the U.S. to go for a class 2 designation you need to have a predicate device meaning there needs to be a comparable device on the market that you can point to. There is no predicate device for the Scout, but there’s an exception in the U.S. FDA called the de novo pathway where if you don’t have a predicate device you can rely on this pathway. It’s much easier than being a class 3. That’s much more expensive. It’s more time consuming and if we can continue for a de novo pathway for the U.S. FDA in the Scout, it’s very good news for shareholders.  

Tracy Weslosky: This is very good news for shareholders, so can you tell us what this process timeline might be like, best-case scenario?

Christopher Moreau: Generally speaking, studies for a class 2 depends on the size of the study. There are some details we’re still working through with the FDA so I’m not going to be able to give you a specific timeline. We are hoping to begin more specific plans for a study in the fall. The size of the study and how long it will take we’ll be able to update the market at that time.

Tracy Weslosky: Of course, you just put out news about a study that you’ve done with Amway. Can you tell us more about this?

Christopher Moreau: Yes. Amway reached out to us and wanted to do a study. They have a device that’s very expensive that can scan a person’s skin and tell whether that skin’s been damaged either by excessive UV, damage below the surface. This is a device that they use that is very expensive. It’s not mobile. They had read about the Scout and….to access the rest of this interview, click here

Disclaimer: Miraculins Inc. is an advertorial member of InvestorIntel.


Tracy Weslosky

Editor:

Tracy Weslosky is the CEO of InvestorIntel Corp., a company that publishes InvestorIntel.com. A leading source for investors, entrepreneurs and industry leaders alike, InvestorIntel is ... <Read more about Tracy Weslosky>


Copyright © 2017 InvestorIntel Corp. All rights reserved. More & Disclaimer »


Comments

  • Mary Patterson

    Really great technology for diabetes. I was diagnosed with type 2 Diabetes and put on Metformin on June 26th, 2014. I started the ADA diet and followed it 100% for a few weeks and could not get my blood sugar to go below 140. Finally i began to panic and called my doctor, he told me to get used to it. He said I would be on metformin my whole life and eventually insulin. At that point i knew something wasn’t right and began to do a lot of research. On April 13th I found this book on http://www.wje592.com/i-am-finally-free-of-diabetes/. I read the book from end to end that night because everything the writer was saying made absolute sense. I started the diet that day and the next morning my blood sugar was down to 100, the next day was in the 90’s and now i have a fasting blood sugar between Mid 70’s and the 80’s. My doctor took me off the metformin after just one week of being on this lifestyle change. I have lost over 30 pounds in a month. I now work out twice a day and still have tons of energy. I have lost 6+ inches around my waist and I am off my high blood pressure medication too. I have about 20 more pounds to go till my body finds its ideal weight. The great news is, this is a lifestyle I can live with, it makes sense and it works. God Bless the writer. I wish the ADA would stop enabling consumers and tell them the truth. You can get off the drugs, you can help yourself, but you have to have a correct lifestyle and diet. No more processed foods.

    June 13, 2015 - 4:00 AM

  • Tracy Weslosky

    Chris is the hardest working CEO I have met in a very — long time. Seriously, this team is at it 24-7. Anyways, I felt I should add my two cents, and also share with InvestorIntel readers that Chris used the test on me and I scored 38.7. So I am fine (today), but it was a great reminder that we should never take our health for granted. Thank you Miraculins!

    June 19, 2015 - 1:04 PM

  • Dan

    Tracy, Seems like it’s taking them a long time to generate any revenue out of their two products though.

    July 1, 2015 - 2:16 AM

Leave a Reply

Your email address will not be published. Required fields are marked *